
Research peptides
P-21
P-21 (also written P021) is a small synthetic peptidergic compound, Ac-DGGL(A)G-NH2, derived from the active region of ciliary neurotrophic factor (CNTF) and carrying an adamantylated glycine. It was designed by Iqbal and colleagues in New York.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 5 mg, lot P21-5-0318: 99.80% purity (RP-HPLC), 5.25 mg measured, identity confirmed by mass spec. Issued 2026-06-17 by Bioviridian Inc.. Verify certificate COA4866
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Alzheimer-type pathology in transgenic mice
- Cognitive aging in rats
- Hippocampal neurogenesis and synaptic plasticity
- Down syndrome and CDKL5 deficiency models
How it is thought to work
The proposed mechanism, reported by the developing group, is inhibition of leukemia inhibitory factor (LIF) signaling and increased brain-derived neurotrophic factor (BDNF) expression, with a resulting decrease in GSK-3beta activity. It has not been examined in humans. A 2024 study in CDKL5-deficient mice found effects in cultured cells but no BDNF increase in vivo and limited behavioral benefit.
Where the research stands
Preclinical research. Published work is limited to cell, mouse and rat studies, nearly all involving one research group. No human trial of this compound was found on ClinicalTrials.gov, and it is not an approved medicine.
Sources
- Kazim SF, et al. (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiology of Disease.
- Bolognin S, et al. (2014). Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging.
- Kazim SF, Iqbal K. (2016). Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Molecular Neurodegeneration.
- Mottolese N, et al. (2024). Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. Journal of Neurodevelopmental Disorders.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
